1. In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens

Sepideh Parvizpour, Jafar Razmara, Mohammad M. Pourseif, Yadollah Omidi*

Bioimpacts. 2019;9(1): 45-56. doi: 10.15171/bi.2019.06

PMCID: PMC6378095 PMID: 30788259 Scopus ID: 85060470196

Article

PDF

Full Text

XML

Cited By:

Using immunoinformatic tools, a multi-epitope peptide vaccine (consisting of CD8+cytotoxic T lymphocytes epitopes, helper epitopes and adjuvant) was designed to combat the triple-negative breast cancer. The vaccine showed acceptable immunogenicity and potential to stimulate both cellular and humoral immune responses.

Original Article

2. Inhibitory effect of miR342 on the progression of triple-negative breast cancer cells in vitro and in the mice model

Zahra Alidoost , Farnoosh Attari* , Fatemeh Saadatpour, Ehsan Arefian

Bioimpacts. 2024;14(1): 27758. doi: 10.34172/bi.2023.27758

PMCID: PMC10844590 PMID: 38327636 Scopus ID: 85182797992

Article

PDF

XML

Cited By:

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons